BACKGROUND:Chimeric antigen receptor T cell therapy is a cutting-edge approach for the treatment of B cell hematological malignancies.These cells efficiently and specifically recognize and kill tumor cells,unrestricted by major histocompatibility complex limitations.OBJECTIVE:To elucidate the structure,developmental history,and marketed progress of chimeric antigen receptor T cells,summarize their long-term efficacy in B cell hematological malignancies treatments,and discuss associated toxicities,recurrence,and mitigation strategies.Additionally,it reviews the advancement of potential targets in B cell hematological malignancies treatments.METHODS:Searches were conducted in PubMed,CNKI,and WanFang databases using the terms"CAR-T,B cell hematological malignancies,toxic side effects,immunotherapy"in Chinese and English,focusing on articles regarding chimeric antigen receptor T cell targets in B-cell malignant tumor treatments.RESULTS AND CONCLUSION:(1)The U.S.Food and Drug Administration and National Medical Products Administration have approved 11 chimeric antigen receptor T cell products,primarily targeting CD19 and B cell maturation antigen targets in B cell hematological malignancies.(2)Long-term follow-up data indicate that chimeric antigen receptor T cell therapy provides a high remission rate and enduring responses in B cell hematological malignancies patients,albeit with recurrence issues due to antigen loss or downregulation.(3)Chimeric antigen receptor T cell therapy is associated with significant toxicities,a high recurrence rate,and drug resistance,constraining its broad application.(4)Future research should concentrate on developing new targets,combined therapies,and strategies to enhance chimeric antigen receptor T cell persistence and antitumor activity.

BACKGROUND:Chimeric antigen receptor T cell therapy is a cutting-edge approach for the treatment of B cell hematological malignancies.These cells efficiently and specifically recognize and kill tumor cells,unrestricted by major histocompatibility complex limitations.OBJECTIVE:To elucidate the structure,developmental history,and marketed progress of chimeric antigen receptor T cells,summarize their long-term efficacy in B cell hematological malignancies treatments,and discuss associated toxicities,recurrence,and mitigation strategies.Additionally,it reviews the advancement of potential targets in B cell hematological malignancies treatments.METHODS:Searches were conducted in PubMed,CNKI,and WanFang databases using the terms"CAR-T,B cell hematological malignancies,toxic side effects,immunotherapy"in Chinese and English,focusing on articles regarding chimeric antigen receptor T cell targets in B-cell malignant tumor treatments.RESULTS AND CONCLUSION:(1)The U.S.Food and Drug Administration and National Medical Products Administration have approved 11 chimeric antigen receptor T cell products,primarily targeting CD19 and B cell maturation antigen targets in B cell hematological malignancies.(2)Long-term follow-up data indicate that chimeric antigen receptor T cell therapy provides a high remission rate and enduring responses in B cell hematological malignancies patients,albeit with recurrence issues due to antigen loss or downregulation.(3)Chimeric antigen receptor T cell therapy is associated with significant toxicities,a high recurrence rate,and drug resistance,constraining its broad application.(4)Future research should concentrate on developing new targets,combined therapies,and strategies to enhance chimeric antigen receptor T cell persistence and antitumor activity.

Lung transplantation is the only effective treatment of end-stage lung diseases. Nevertheless, shortage of donor lungs has become increasingly prominent worldwide. A large quantity of patients died while waiting for lung transplantation. Urgent lung transplantation is a prioritized allocation strategy for donor lung transplantation according to the urgency of diseases, aiming to shorten the waiting time for donor lungs and reduce the fatality of patients on the waiting list for lung transplantation. However, no consensus has been reached worldwide on the definition, criteria and application of the terminology of urgent lung transplantation. In addition, the survival and net benefits of lung transplant recipients based on this allocation system are still controversial. On the basis of previous clinical research on urgent lung transplantation, the definition criteria, risk factors, survival outcomes, limitations and optimization measures were explicitly elucidated in this article, aiming to provide theoretical reference for comprehensive evaluation of the feasibility of urgent lung transplantation and further optimizing the allocation system of donor lungs.

Objective:To compare three kinds of stress injury risk factors assessment scales during intraoperative period, and to provide evidence for the prevention of intraoperative stress injury.Methods:Three assessment tools (Waterlow Risk Factor Assessment Scale, Munro Pressure Ulcer Assessment Scale and Scott Triggers Evaluation Scale) were used to assess the risk degree of 173 surgical patients in the Operating Room of Zhongshan Hospital Affiliated to Fudan University from January 2018 to June 2019. After the operation, a whole-body skin examination was performed to record the occurrence of pressure ulcer, and the reliability, validity, and prediction effect of every scale were compared.Results:The retest reliability of Scott Triggers Evaluation Scale and Munro Pressure Ulcer Assessment Scale was respectively 0.932 and 0.992, the expert content validity was respectively 0.759 and 0.705, the calibration correlation validity was respectively 0.381 and 0.190, the sensitivity was respectively 0.74 and 0.32 and specificity was respectively 0.58 and 0.89. The area under the ROC curve of Scott Triggers Evaluation Scale and Munro Pressure Ulcer Assessment Scale was larger than that of Waterlow Risk Factor Assessment Scale, which was 0.714 and 0.711, respectively.Conclusions:Scott Triggers Evaluation Scale and Munro Pressure Ulcer Assessment Scale can be used to evaluate the stress injury of surgical patients. At the same time, Scott Triggers Evaluation Scale is more accurate and convenient than the Munro Pressure Ulcer Evaluation Scale. Thus, Scott Triggers Evaluation Scale is recommended for clinical application.

0.05).Our results showed that,for recommended oral doses of ciprofloxacin and moxifloxacin,44.2% of E.coli isolates from the intestine of the health population,and 29.5%,18.7% and 10.7% of isolates from the three sterile sites of the patients,would be selected as resistant mutants.When ciprofloxacin and moxifloxacin were taken by injection route,the ratio of the selection of resistant mutants would be 9.3% for E.coli isolates from the intestine of the health population and 8.2%,6.2% and 8.9% for the three sterile sites of the patients,respectively.The maximum attainable concentration of levofloxacin in serum showed little distinction between the oral and the other routes.CONCLUSIONS The values of MIC and MPC of three fluoroquinolones in E.coli isolates from different populations and sites show no association.The values of MPC couldn't be predicted by the MIC.The values of MPC and MPC90 of three drugs show no significant discrepancy for tested isolates,these E.coli strains are isolated from the intestine of heath persons,and from the blood,ascites,bile of patients.

OBJECTIVE To investigate the susceptibility of Enterococcus faecalis and E.faecium isolated from system and urinary tract infected patients and provide data for anti-infection therapy.METHODS The susceptibility(MIC) of 249 Enterococcus strains was tested by agar dilution method.RESULTS All 249 strains of Enterococcus(117 strains of E.faecalis and 132 strains of E.faecium) were isolated from urinary tract or systemic infection patients.The isolated rate of E.faecalis(68.4%) was higher than that of E.faecium(50.0%) in urinary tract isolates.Meanwhile,the isolated rate of E.faecium(50.0%) was obviously higher than that of E.faecalis(31.6%) in systemic infection isolates.The drug susceptibility rate of E.faecalis was higher than that of E.faecium to gatifloxacin,ciprofloxacin,penicillin,ampicillin and high-level gentamicin but lower for minocycline.All Enterococcus were susceptible to vancomycin,teicoplanin and linezolid.They were almost 100.0% resistant to erythromycin.The susceptibility rate of E.faecalis(39.5%)was higher than E.f aecium(15.3%) to high-level gentamicin.The susceptibility rate of E.faecalis isolated from blood was higher than the strains isolated from urinary tract to all antibiotics.E.faecium isolated form blood was almost 100% resistant to gatifloxacin,ciprofloxacin,penicillin,ampicillin and erythromycin.CONCLUSIONS The drug susceptibility of E.faecalis and E.faecium which cause systemic and urinary tract infection is different.The available therapy project should be selected based on the resistance character.At present,vancomycin,teicoplanin and linezolid are the best choice for treatment against the infection caused by Enterococcus.